Evidence map›Paper›PMID 40928125›Full record

ArticleAnnals of clinical and translational neurology2025

Plasma p-tau181 as a Marker of Conversion to Alzheimer's Disease Dementia and Worsening in Cognitive Functions in Subjective Cognitive Decline and Mild Cognitive Impairment: A Longitudinal Study.

Giulia Giacomucci, Assunta Ingannato, Chiara Crucitti, Silvia Bagnoli, Elisa Marcantelli, Sonia Padiglioni, Valentina Moschini, Carmen Morinelli, Laura Falsini, Sandro Sorbi and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of clinical and translational neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Giulia GiacomucciDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.ORCID 0000-0002-8711-331X
Assunta IngannatoDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
Chiara CrucittiDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
Silvia BagnoliDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
Elisa MarcantelliDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
Sonia PadiglioniResearch and Innovation Centre for Dementia-CRIDEM, AOU Careggi, Florence, Italy.
Valentina MoschiniResearch and Innovation Centre for Dementia-CRIDEM, AOU Careggi, Florence, Italy.
Carmen MorinelliResearch and Innovation Centre for Dementia-CRIDEM, AOU Careggi, Florence, Italy.
Laura FalsiniUniversity of Florence, Florence, Italy.
Sandro SorbiDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
Valentina BertiDepartment of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.
Benedetta NacmiasDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
Valentina BessiDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.

Funding

Ministero dell'Università e della Ricerca B83C22004800006Regione Toscana D19G22000640002
6 · The paper itself

Abstract

backgroundPlasma p-tau181 has proven to be a promising diagnostic and prognostic tool in the earliest phases of Alzheimer's disease (AD). We aimed to evaluate the prognostic role of p-tau181 in predicting conversion to AD dementia and worsening in cognition in mild cognitive impairment (MCI) and subjective cognitive decline (SCD).

methodsWe consecutively enrolled 163 patients (50 SCD, 70 MCI, and 43 AD-demented (AD-d)), who underwent plasma p-tau181 analysis with the Simoa assay. Patients were classified according to the Revised Criteria of the Alzheimer's Association Workgroup as Core1+ or Core1- (based on amyloid-PET, CSF Aβ42/Aβ40, CSF p-tau181/Aβ42).

resultsPlasma p-tau181 levels were significantly influenced by Core1 status (B = 1.41, p < 0.001) and clinical diagnosis (B = 0.63, p < 0.001). Plasma p-tau181 was highly accurate in discriminating between Core1+ and Core1- patients (AUC = 0.88 [95% CI 83.00-94.00]) with a cut-off value of 2.25 pg/mL presenting good accuracy (85.90%), specificity (74.58%), and excellent sensitivity (92.78%). Classifying patients according to p-tau181 cut-off, we found that p-tau181+ patients showed an increased risk of converting to AD dementia (HR = 11.65, p = 0.018). Moreover, SCD p-tau181+ worsened over time in tasks assessing long-term verbal (p = 0.012) and spatial memory (p = 0.009).

conclusionsPlasma p-tau181 is not only a good diagnostic marker for AD pathology, but it also plays a role as a predictor of both conversion to AD dementia and of worsening of cognitive performance since the earliest phase of AD.

Indexed as

Alzheimer DiseaseCognitive Dysfunctiontau ProteinsAgedAged, 80 and overAmyloid beta-PeptidesBiomarkersDisease ProgressionFemaleHumansLongitudinal StudiesMaleMiddle AgedAmyloid beta-PeptidesBiomarkersMAPT protein, humantau ProteinsAlzheimer's diseasecognitive worseningmild cognitive impairmentplasma biomarkersplasma p‐tau181subjective cognitive decline

Identifiers

PMID40928125
PMCPMC12698954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.